While GLP-1 drugs may suppress appetite, they dont address underlying issues like emotional eating or trauma
Tirzepatide (Dual GIP/GLP-1 Agonist) Tirzepatide is a dual GIP/GLP-1 receptor agonist FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity, 2023)
Your GP might consider: Adjusting your fluoxetine dose Switching to an alternative antidepressant with different weight effects Addressing other medications that might contribute to weight gain Never adjust or stop your medication without medical supervision, as this can lead to withdrawal symptoms or relapse of your mental health condition
Keytruda is the first anti-PD-1 therapy approved in combination with chemoradiotherapy (CRT) for this indication, according to Mercks announcement
Important Notes Important Notes These practical guidelines are included to support consistency, dosing accuracy, and proper handling throughout an educational, research-style peptide protocol